The corporate has additionally give you a affected person help programme which is able to permit sufferers and establishments who’ve restricted assets to buy the drugs at a extremely subsidised fee, BDR Prescription drugs mentioned in a press release.
BDR pharma has acquired an approval from the Medication Controller Normal of India (DCGI) to fabricate Favipiravir to deal with delicate to reasonable sufferers with COVID-19 signs. The drug has been launched beneath the model title ‘BDFAVI’, it added.
“BDR has been on the forefront in benefiting sufferers on this pandemic and supporting India’s combat in opposition to COVID-19. This launch additional strengthens our dedication to the sufferers to supply higher outcomes for sufferers with delicate to reasonable COVID signs in India,” BDR Prescription drugs CMD Dharmesh Shah mentioned.
The corporate has developed Favipiravir tablets in 200 mg strengths with a strip of 10 tablets, BDR Prescription drugs mentioned.